Drugs / Sym013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02906670 | Nov 2016 → Jun 2019 | — | Symphogen A/S | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02906670 ↗ |
| Modality | Monoclonal antibody | “Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs)” NCT02906670 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT02906670 ↗ |